Glofitamab CD20-TCB bispecific antibody - PubMed
Glofitamab is a novel full-length IgG-like CD20-CD3 bispecific with a unique 2:1 configuration that provides an extended half-life and superior CD20 binding. Phase 1 monotherapy and …
CD20 Tcb (RG6026), a Novel - American Society of Hematology
2016年12月2日 · Combination studies of CD20 TCB with PD-L1 blocking antibody led to more profound and faster tumor growth inhibition. Taken together, the preclinical data show that …
CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be …
2019年11月13日 · CD20-TCB offers the potential for increased tumor antigen avidity, rapid T-cell activation, and enhanced tumor cell killing versus other bispecific formats. CD20-TCB has …
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation …
2018年10月1日 · Here, we present a next-generation CD20-targeting TCB (CD20-TCB) with significantly higher potency and a novel approach enabling safer administration of such potent …
CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for …
2016年12月2日 · CD20 TCB is a new bispecific antibody with IgG-like pharmacokinetic properties whose unique "2:1" structure leads to increased tumor antigen avidity, T cell activation, and …
罗氏新型Prot-2+1 TCB抗体 - 健康界
2021年4月13日 · Glofitamab是靶向CD20XCD3的T细胞双特异抗体，抗体的结构形式为“2+1” （CD20-TCB） ，即有两个CD20结合位点和一个CD3结合位点。 一期临床数据显示该抗体在B …
CD20 Tcb (RG6026)，一种用于治疗 B 细胞恶性肿瘤的新型“2:1”T
CD20 TCB is a new bispecific antibody with IgG-like pharmacokinetic properties whose unique "2:1" structure leads to increased tumor antigen avidity, T cell activation, and tumor cell killing, …
CD20-Tcb (RG6026), a Novel - American Society of Hematology
2018年11月29日 · CD20-TCB (RG6026) is a novel T-cell-engaging bispecific antibody whose "2:1" format possesses two CD20 binders in addition to a CD3 binder, enabling increased …
CD20-Tcb (RG6026), a Novel “2:1” Format T-Cell-Engaging …
2018年11月29日 · CD20-TCB (RG6026) is a novel T-cell-engaging bispecific antibody whose "2:1" format possesses two CD20 binders in addition to a CD3 binder, enabling increased …
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation …
2018年10月1日 · We developed a potent, next-generation, half-life extended CD20-targeting TCB antibody (CD20-TCB), based on the 2:1 molecular format, which has significantly superior …